Table 2.
Enrichment by pathway maps of up-regulated genes.
| Maps | p-Value | Genes Involved |
|---|---|---|
| Cell cycle_Start of DNA replication in early S phase | 2.68 × 10−14 | MCM4, MCM3, Cdt1, MCM2, ORC1L, Histone H1, MCM5, E2F1, CDC45L, MCM4/6/7 complex |
| Cell cycle_Transition and termination of DNA replication | 1.86 × 10−6 | MCM2, PCNA, FEN1, POLD cat (p125), DNA ligase I |
| NETosis in SLE | 3.7 × 10−6 | Histone H4, Histone H2, Histone H2A, PKC, Histone H1 |
| dCTP/dUTP metabolism | 2.29 × 10−5 | Ribonucleotide reductase, RRM2, Small RR subunit, RRM1, POLD cat (p125), POLA2 |
| dATP/dITP metabolism | 4.8 × 10−5 | Ribonucleotide reductase, RRM2, Small RR subunit, RRM1, POLD cat (p125), POLA2 |
| Cell cycle_Sister chromatid cohesion | 6.3 × 10−4 | CHTF18, PCNA, Histone H1 |
| Immune response_IFN-alpha/beta signaling via PI3K and NF-kB pathways | 6.8 × 10−4 | DHFR, PCNA, b-Myb, E2F1, ISG15 |
| Cytoskeleton remodeling_Neurofilaments | 9.3 × 10−4 | Tubulin beta, Vimentin, NEFL |
| Transcription_Effect of Folic acid on genome stability | 0.001 | DHFR, HCP1, TYSY, ADH1 |
| Immune response_IL-4-induced regulators of cell growth, survival, differentiation and metabolism | 0.001 | MCM4, MCM6, MMP-13, MCM5 |
| Folic acid metabolism | 0.001 | C1TC, DHFR, HCP1, SLC19A1 |
| DNA damage_Role of Brca1 and Brca2 in DNA repair | 0.001 | Rad51, PCNA, FANCD2 |
| Development_Transcription regulation of granulocyte development | 0.001 | c-Myb, PKC, E2F1 |
| Transcription_Negative regulation of HIF1A function | 0.002 | MCM3, MCM2, MCM7, MCM5 |
| Inhibition of neutrophil migration by proresolving lipid mediators in COPD | 0.002 | TLN2, Talin, PKC, cPKC |
| Signal transduction_HTR2A signaling outside the nervous system | 0.002 | PKC-beta, PKC, cPKC (conventional), E2F1 |
| DNA damage_Nucleotide excision repair | 0.003 | PCNA, POLD cat (p125), DNA ligase I |
| Cell adhesion_Cell-matrix glycoconjugates | 0.003 | CCL5, MMP-1, ECM1 |
| Development_Gastrin in differentiation of the gastric mucosa | 0.003 | PKC-beta, PKC, cPKC |
| Complement pathway disruption in thrombotic microangiopathy | 0.003 | CCL5, PKC, cPKC |
| Immune response_IL-1 signaling pathway | 0.003 | CCL5, SPHK1, MMP-1, MMP-13 |
| Oxidative stress_Activation of NOX1, NOX5, DUOX1 and DUOX2 NADPH Oxidases | 0.004 | PKC-beta, PKC, cPKC |
| Development_VEGF signaling and activation | 0.004 | PKC-beta, SPHK1, PKC |
| Glomerular injury in Lupus Nephritis | 0.005 | CCL5, PKC-beta1, MMP-1, PKC-beta2 |
| Apoptosis and survival_DNA-damage-induced apoptosis | 0.005 | FANCD2, E2F1 |
| Transcription_Assembly of RNA Polymerase II preinitiation complex on TATA-less promoters | 0.008 | DHFR, PCNA |
| Immune response_IL-16 signaling pathway | 0.009 | CCL5, PKC, cPKC |
| DNA damage_Mismatch repair | 0.009 | EXO1, PCNA |